Oliver Scherf-Clavel, PhD

LMU Munich
Munich, Germany

Disclosure information not submitted.

Presentation(s):

• ORF37-03 - Cabozantinib in Advanced Adrenocortical Carcinoma after standard therapy: final phase 2 trial results and the relevance of prior mitotane use

  Sunday, June 14, 2026
  3:30 PM - 4:15 PM CT